ACCOUNTS - Final Accounts preparation

Analysis of the maturity of loans is given below:

Registered number: 14759302

HEER PHARMA LTD

UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 MARCH 2025

HEER PHARMA LTD

REGISTERED NUMBER: 14759302

BALANCE SHEET

AS AT 31 MARCH 2025

	2025	2025	2024	2024
Note	£	£	£	£

Fixed assets
Investments	4		1,085,689		1,085,689
Current assets
Cash at bank and in hand	5	212		40
Creditors: amounts falling due within one year	6	(846,229)		(784,232)
Net current liabilities			(846,017)		(784,192)
Total assets less current liabilities			239,672		301,497
Creditors: amounts falling due after more than one year	7		(288,017)		(325,299)

Net liabilities			(48,345)		(23,802)

Capital and reserves
Called up share capital	1	1
Profit and loss account	(48,346)	(23,803)
	(48,345)	(23,802)

Page 1

HEER PHARMA LTD

REGISTERED NUMBER: 14759302

BALANCE SHEET (CONTINUED)

AS AT 31 MARCH 2025

The director considers that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by:

................................................

H Joshi

Director

Date: 9 December 2025

The notes on pages 3 to 5 form part of these financial statements.

Page 2

HEER PHARMA LTD

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2025

1.	General information

Heer Pharma Ltd is a private company, limited by shares, registered in England and Wales. The company's registered address is 171 Nimrod Road, London, SW16 6TH.

2.Accounting policies

2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

2.2

Exemption from preparing consolidated financial statements

The Company, and the Group headed by it, qualify as small as set out in section 383 of the Companies Act 2006 and the parent and Group are considered eligible for the exemption to prepare consolidated accounts.

2.3

Going concern

After making enquiries, the director has a reasonable expectation that the Company has adequate resources to continue in operational existence and meet its liabilities as they fall due for the foreseeable future, being a period of at least twelve months from the date these financial statements were approved. Accordingly, she continues to adopt the going concern basis in preparing the financial statement.

2.4

Finance costs

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

2.5

Borrowing costs

All borrowing costs are recognised in profit or loss in the year in which they are incurred.

2.6

Valuation of investments

Investments in subsidiaries are measured at cost less accumulated impairment.

Page 3

HEER PHARMA LTD

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2025

2.Accounting policies (continued)

2.7

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

2.8

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

Employees

The Company has no employees other than the directors, who did not receive any remuneration (2024 - £NIL).

4.	Fixed asset investments

		Unlisted investments
		£
	Cost or valuation
	At 1 April 2024	1,085,689
	At 31 March 2025	1,085,689

5.	Cash and cash equivalents
		2025	2024
		£	£

	Cash at bank and in hand	212	40

Page 4

HEER PHARMA LTD

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2025

6.	Creditors: Amounts falling due within one year
		2025	2024
		£	£

Bank loan	36,695	13,000
Other creditors	809,534	770,272
Accruals and deferred income	-	960
	846,229	784,232

Secured loan
The bank loan is secured by a fixed charge over the property and a floating charge over the property and undertakings of the company.

7.	Creditors: Amounts falling due after more than one year
		2025	2024
		£	£

	Bank loan	288,017	325,299

Secured loan
The bank loan is secured by a fixed charge over the property and a floating charge over the property and undertakings of the company.

Amounts falling due within one year
Bank loans	36,695	13,000


Amounts falling due after more than 5 years
Bank loans	288,017	325,299

Page 5